Therapy of exudative age-related macular degeneration (AMD) with anti-vascular endothelial growth factor (VEGF) substances has evolved to an effective and widespread treatment in the last years, allowing preservation or even improvement of visual acuity in the short and long term [1–3]. This evidence concerns the gene VEGFA and age-related macular degeneration.